Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Aumolertinib - Jiangsu Hansoh Pharmaceutical

Next Previous
Drug Profile

Aumolertinib - Jiangsu Hansoh Pharmaceutical

Alternative Names: Almonertinib; AMEILE; Amerol; Aumolertinib mesylate - Jiangsu Hansoh Pharmaceutical; EQ-143; HS-10206; HS-10296; HS-10296 mesylate

Latest Information Update: 11 Mar 2024

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Jiangsu Hansoh Pharmaceutical
  • Developer EQRx; Henan Cancer Hospital; Jiangsu Hansoh Pharmaceutical
  • Class Acrylamides; Amines; Antineoplastics; Cyclopropanes; Indoles; Pyrimidines; Small molecules
  • Mechanism of Action Epidermal growth factor receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Marketed Non-small cell lung cancer
  • Phase I Solid tumours
  • Clinical Phase Unknown Meningeal carcinomatosis

Most Recent Events

  • 20 Oct 2023 Efficacy and adverse event data from a phase III trial in Non-small cell lung cancer presented at the 48th European Society for Medical Oncology Congress (ESMO-2023)
  • 31 Aug 2023 EQRx International terminates a phase III trial in Non-small cell lung cancer (Monotherapy, Late-stage disease, Metastatic disease, Recurrent, First-line therapy) in USA (PO) (NCT05493501)
  • 08 May 2023 Aumolertinib - Jiangsu Hansoh Pharmaceutical is available for licensing in World (excluding China, Hong Kong, Macau, Taiwan) as of 08 May 2023
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Legal
Back to top